Cargando…

Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine

There is a need for fast-acting, non-oral medication options for migraine because some attacks develop rapidly and some are accompanied by nausea, vomiting, and gastroparesis, which can hinder oral medication uptake and absorption. The most commonly prescribed migraine medications are oral triptans,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tepper, Stewart J, Johnstone, Merrilee R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937501/ https://www.ncbi.nlm.nih.gov/pubmed/29760572 http://dx.doi.org/10.2147/MDER.S130900

Ejemplares similares

Improved Pharmacokinetics of Sumatriptan With Breath Powered™ Nasal Delivery of Sumatriptan Powder
por: Obaidi, Mohammad, et al.
Publicado: (2013)

AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks
por: Tepper, Stewart J, et al.
Publicado: (2015)

Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine
por: Assadpour, Sara, et al.
Publicado: (2022)

A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)
por: Cady, Roger K, et al.
Publicado: (2015)

Functional Hybrid Nanoemulsions for Sumatriptan Intranasal Delivery
por: Ribeiro, Lígia N. M., et al.
Publicado: (2020)

Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache
por: Moore, Johanna C, et al.
Publicado: (2012)

Freeze-Dried K-Carrageenan/Chitosan Polyelectrolyte Complex-Based Insert: A Novel Intranasal Delivery System for Sumatriptan Succinate
por: Alavi, Sonia, et al.
Publicado: (2018)

Spray Dried Levodopa-Doped Powder Potentially for Intranasal Delivery
por: Liu, Xuan, et al.
Publicado: (2022)

Efficacy of Sumatriptan/Placebo versus Sumatriptan/Propofol Combination in Acute Migraine; a Randomized Clinical Trial
por: Farahmand Rad, Reza, et al.
Publicado: (2022)

Influence of sumatriptan on the autonomic system during migraine attacks
por: Dalla Volta, G., et al.
Publicado: (2006)

Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder
por: Ball, Jordan P., et al.
Publicado: (2017)

The Use of Neuroimaging for Predicting Sumatriptan Treatment Response in Patients With Migraine
por: Wu, Jr-Wei, et al.
Publicado: (2022)

Sumatriptan–naproxen fixed combination for acute treatment of migraine: a critical appraisal
por: Khoury, Chaouki K, et al.
Publicado: (2010)

Nasal Delivery of Acute Medications for Migraine: The Upper Versus Lower Nasal Space
por: Martin, Vincent, et al.
Publicado: (2021)

Pharmacokinetics study of chitosan-coated liposomes containing sumatriptan in the treatment of migraine
por: Assadpour, Sara, et al.
Publicado: (2022)

Development of Intranasal Levothyroxine Powder Delivery for Hypothyroidism
por: Imran, Syed Ali, et al.
Publicado: (2021)

Intranasal Delivery of Chitosan Nanoparticles for Migraine Therapy
por: Gulati, Neha, et al.
Publicado: (2013)

Application of Design of Experiment for Polyox and Xanthan Gum Coated Floating Pulsatile Delivery of Sumatriptan Succinate in Migraine Treatment
por: Jagdale, Swati C., et al.
Publicado: (2014)

Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients
por: Sternieri, E., et al.
Publicado: (2005)

Metoclopramide versus sumatriptan for treatment of migraine headache: A randomized clinical trial
por: Talabi, Saeid, et al.
Publicado: (2013)

Cilostazol induced migraine does not respond to sumatriptan in a double blind trial
por: Falkenberg, Katrine, et al.
Publicado: (2018)

Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
por: Brand-Schieber, Elimor, et al.
Publicado: (2016)

Predicting Sumatriptan Responsiveness Based on Structural Connectivity in Patients Newly Diagnosed With Migraine
por: Lee, Dong Ah, et al.
Publicado: (2023)

Breath Powered Nasal Delivery: A New Route to Rapid Headache Relief
por: Djupesland, Per G, et al.
Publicado: (2013)

Sumatriptan (50 and 100 mg) in repeated migraine attacks: a patient preference study
por: Zanchin, Georgio, et al.
Publicado: (2000)

Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment
por: Tfelt-Hansen, Peer
Publicado: (2007)

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
por: Munjal, Sagar, et al.
Publicado: (2017)

Metabolism of sumatriptan revisited
por: Pöstges, Timo, et al.
Publicado: (2023)

Investigation of the immunoreactivities of NOS enzymes and the effect of sumatriptan in adolescent rats using an experimental model of migraine
por: Kurul, Semra Hiz, et al.
Publicado: (2008)

The effect of intravenous administration of liposomal curcumin in addition to sumatriptan treatment in an experimental migraine model in rats
por: Bulboacă, Adriana E, et al.
Publicado: (2018)

A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies
por: Nižić Nodilo, Laura, et al.
Publicado: (2021)

Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine
por: Cady, Roger K., et al.
Publicado: (2017)

Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine
por: Vikelis, Michail, et al.
Publicado: (2012)

A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose
por: Lapidot, Tair, et al.
Publicado: (2022)

Managing migraine headaches experienced by patients who self–report with menstrually related migraine: a prospective, placebo–controlled study with oral sumatriptan
por: Dowson, A. J., et al.
Publicado: (2005)

Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs
por: Andre, Anthony D, et al.
Publicado: (2017)

Strategies of care for acute treatment of migraine
por: Tepper, Stewart J., et al.
Publicado: (2002)

Comparison between Intravenous Sodium Valproate and Subcutaneous Sumatriptan for Treatment of Acute Migraine Attacks; Double-Blind Randomized Clinical Trial
por: Rahimdel, Abolghasem, et al.
Publicado: (2014)

Patient Factors in the Dose Selection of Oral Sumatriptan for Acute Migraine: A Post Hoc Analysis of Two Randomized Controlled Studies
por: Fisher, Matt, et al.
Publicado: (2023)

A Comparison of the Cost-Effectiveness of Almotriptan and Sumatriptan in the Treatment of Acute Migraine Using a Composite Efficacy/Tolerability End Point
por: Williams, Paul, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_9dnc1vt9lj6ioedjrgf1of0gn7